ORIC Announces Initial Phase 1b Data For ORIC-944; Says Demonstrated 'potential best-in-class profile, including half-life >10 hours, robust target engagement and well tolerated safety profile, supporting advancement for combination development'
Portfolio Pulse from Benzinga Newsdesk
ORIC Pharmaceuticals announced initial Phase 1b data for its product ORIC-944, highlighting a potential best-in-class profile with a half-life greater than 10 hours, robust target engagement, and a well-tolerated safety profile. The company plans to advance the product for combination development.
January 08, 2024 | 1:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ORIC Pharmaceuticals' announcement of positive initial Phase 1b data for ORIC-944 indicates a strong potential for the product, which may lead to positive investor sentiment and an increase in stock price in the short term.
The announcement of positive clinical trial results typically leads to increased investor confidence in a pharmaceutical company's pipeline. ORIC-944's reported best-in-class profile and safety could make it an attractive investment, potentially leading to a short-term increase in ORIC's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100